InvestorsHub Logo
Followers 14
Posts 649
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Thursday, 12/03/2015 12:34:31 PM

Thursday, December 03, 2015 12:34:31 PM

Post# of 461943
"While we remain focused on Alzheimer’s, the remarkably fast onset of clinical effect of ANAVEX 2-73 increases our options to potentially pursue additional indications for diseases characterized by working memory impairment and may enable clinical trials to be completed within shorter time frames.”

This has me thinking, with the quick effect on working memory, by how much could this potentially shorten clinical trials ? i.e. "shorter time frames"? Could this mean a 3 month phase three, then approval with an ongoing extension parallel to the approval?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News